BioLineRx Ltd. (BLRX): Price and Financial Metrics
BLRX Price/Volume Stats
| Current price | $0.60 | 52-week high | $2.53 |
| Prev. close | $0.61 | 52-week low | $0.59 |
| Day low | $0.60 | Volume | 65,553 |
| Day high | $0.62 | Avg. volume | 392,889 |
| 50-day MA | $1.02 | Dividend yield | N/A |
| 200-day MA | $1.42 | Market Cap | 47.96M |
BLRX Stock Price Chart Interactive Chart >
BioLineRx Ltd. (BLRX) Company Bio
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company was founded in 2003 and is based in Modiin, Israel.
Latest BLRX News From Around the Web
Below are the latest news stories about BIOLINERX LTD that investors may wish to consider to help them evaluate BLRX as an investment opportunity.
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call TranscriptBioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript November 20, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2023 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] I would […] |
BLRX: A Series of Fortunate EventsBy John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 3Q:23 Operational and Financial Results Activity stepped up substantially following BioLineRx Ltd.’s (NASDAQ:BLRX) report of second quarter results. Shortly after the report, the FDA approved Aphexda and BioLineRx announced the closing of the Asia deal with Gloria Biosciences. Data for the collaboration with Columbia |
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates. |
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open. |
3 Tech Stocks That Wall Street Loves More Than NvidiaPurchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market. |
BLRX Price Returns
| 1-mo | -41.75% |
| 3-mo | -48.28% |
| 6-mo | -54.20% |
| 1-year | -44.44% |
| 3-year | -80.20% |
| 5-year | -89.04% |
| YTD | -61.78% |
| 2023 | 166.10% |
| 2022 | -71.08% |
| 2021 | -19.05% |
| 2020 | 12.00% |
| 2019 | -65.91% |
Loading social stream, please wait...